OncologyPro 9/3/11 8:55 AM



Search term	
-------------	--

GOOD SCIENCE
BETTER MEDICINE
BEST PRACTICE

Oncology News Research Guidelines Publications & CME Meeting Resources Practice Tools Slide Resources

>> HOME > MEETING RESOURCES > MEETING ABSTRACTS > IMPAKT - BREAST CANCER CONFERENCE - 2011 > FAVOURABLE ANTI-CANCER ACTIVITY OF FERMENTED WHEAT GERM FREEZE-DRIED EXTRACT (AVEMAR LYOPHILISATE) IN TRIPLE-NEGATIVE BREAST CANCER CELLS

Favourable anti-cancer activity of fermented wheat germ freeze-dried extract (avemar lyophilisate) in triple-negative breast cancer cells

Publication date: May 01, 2011

Publisher: European Society for Medical Oncology

Authors: Z. Bago-Horvath; B. Forstner; M. Kalipciyan; A. Bedeir; M. Gruscj; O.Komina; J. Wesierska-

Gadek; T. Szekeres; M. Hidvegi; R. Mader

Full Text

Description

Objective: The fermented wheat germ extract, which is the active ingredient of nutraceuticals widely used by cancer patients in Europe, Korea and the United States, possesses cytotoxic and anti-metastatic effects in various human malignancies. In estrogen responsive MCF-7 breast cancer cells, it has been shown to potentiate the induction of apoptosis by tamoxifen. However, its effects in triple-negative and Her2-overexpressing breast cancer cells and interactions with chemotherapy have not been investigated until now.

Methods: Cytotoxicity of Avemar lyophilisate alone and in combination with docetaxel was assessed by MTT and clonogenic assays in MCF-7 estrogen responsive, HCC-38 triple-negative and SKBR-3 Her2/neu overexpressing cells. Cell cycle phase distribution was determined by FACS. Apoptosis-associated activation of caspase-3/7 was measured by Caspase-Glo Assay. Inhibition of tumor cell invasion was quantified using the ORIS Cell Invasion kit.

Results: Avemar lyophilisate exhibited highest cytotoxic activity against triple negative HCC-38 cells in MTT and clonogenic assays with IC50 values of 180 and 15 Ig/ml, respectively, indicating likely clinical activity. In combination with docetaxel, additive and marginally synergistic effects were demonstrated in triple-negative HCC-38 and Her2/neu overexpressing SKBR-3 cells, whereas in the estrogen responsive MCF-7 cell line, cytotoxic activity of docetaxel was antagonized by Avemar lyophilisate. Perturbations in cell cycle phase distribution were differentially regulated by Avemar lyophilisate in estrogen receptor negative HCC-38, SKBR-3 and in estrogen receptor expressing MCF-7 cells, which was associated with altered activation of caspase-3/7. Invasive capacity of breast cancer cells was inhibited by Avemar lyophilisate in all three cancer cell lines investigated in a dose-independent manner.

Conclusions: Avemar lyophilisate exerts highest anti-cancer activity against triple negative HCC-38 human breast cancer cells. Due to its likely clinical activity against this human malignancy, further investigation of Avemar lyophilisate in triple-negative breast cancer is warranted.

Search within Meeting Abstracts

Related Content

Please login to access this content

About ONCOLOGY PRO About ESMO Join ESMO Contact Us Conditions of Use Sitemap Sponsors

ESMO is a Swiss-registered not-for-profit organization. All funding for this site is provided directly by ESMO. Via L. Taddei 4, 6962 Viganello - Lugano - CH © Copyright 2011 European Society for Medical Oncology. All rights reserved worldwide.